Is ADCT or ELUT more profitable?

Elutia has a net margin of 312.09% compared to ADC Therapeutics' net margin of -173.02%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics -173.02% N/A -44.70% Elutia 312.09% N/A -53.97%

Does the media refer more to ADCT or ELUT?

In the previous week, Elutia had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for Elutia and 1 mentions for ADC Therapeutics. Elutia's average media sentiment score of 0.33 beat ADC Therapeutics' score of 0.00 indicating that Elutia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elutia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ELUT or ACB?

Elutia presently has a consensus price target of $6.00, indicating a potential upside of 531.58%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ELUT or ACB more profitable?

Elutia has a net margin of 312.09% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 312.09% N/A -53.97% Aurora Cannabis -33.57% 0.10% 0.07%

Is NRXP or ELUT more profitable?

Elutia has a net margin of 312.09% compared to NRx Pharmaceuticals' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Elutia 312.09% N/A -53.97%

Does the media refer more to NRXP or ELUT?

In the previous week, NRx Pharmaceuticals had 1 more articles in the media than Elutia. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 3 mentions for Elutia. NRx Pharmaceuticals' average media sentiment score of 1.21 beat Elutia's score of 0.33 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELUT or ABOS?

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Elutia. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 3 mentions for Elutia. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat Elutia's score of 0.33 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MIST or ELUT?

In the previous week, Elutia had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 3 mentions for Elutia and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Elutia's score of 0.33 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Elutia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Elutia (ELUT) Competitors

$0.95 +0.02 (+2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$0.96 +0.01 (+0.53%)

As of 04:34 PM Eastern

Compare

ELUT vs. ADCT, ACB, NRXP, ABOS, and MIST

Should you buy Elutia stock or one of its competitors? MarketBeat compares Elutia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Elutia include ADC Therapeutics (ADCT), Aurora Cannabis (ACB), NRx Pharmaceuticals (NRXP), Acumen Pharmaceuticals (ABOS), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry.

How does Elutia compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by insiders. Comparatively, 17.8% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ADC Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market. Comparatively, Elutia has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

In the previous week, Elutia had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for Elutia and 1 mentions for ADC Therapeutics. Elutia's average media sentiment score of 0.33 beat ADC Therapeutics' score of 0.00 indicating that Elutia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADC Therapeutics currently has a consensus price target of $6.25, indicating a potential upside of 390.20%. Elutia has a consensus price target of $6.00, indicating a potential upside of 531.58%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elutia has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.99	-$142.62M	-$1.05	N/A
Elutia	$12.46M	3.26	$53.38M	$0.86	1.10

Elutia has a net margin of 312.09% compared to ADC Therapeutics' net margin of -173.02%.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Elutia	312.09%	N/A	-53.97%

Summary

Elutia beats ADC Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Elutia compare to Aurora Cannabis?

Elutia (NASDAQ:ELUT) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Elutia has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Elutia has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.46M	3.26	$53.38M	$0.86	1.10
Aurora Cannabis	$247.82M	0.66	-$88.13M	-$1.56	N/A

Elutia presently has a consensus price target of $6.00, indicating a potential upside of 531.58%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Elutia had 3 more articles in the media than Aurora Cannabis. MarketBeat recorded 3 mentions for Elutia and 0 mentions for Aurora Cannabis. Elutia's average media sentiment score of 0.33 beat Aurora Cannabis' score of 0.00 indicating that Elutia is being referred to more favorably in the media.

Company	Overall Sentiment
Elutia	Neutral
Aurora Cannabis	Neutral

74.0% of Elutia shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 17.8% of Elutia shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Elutia has a net margin of 312.09% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Aurora Cannabis	-33.57%	0.10%	0.07%

Summary

Elutia beats Aurora Cannabis on 12 of the 15 factors compared between the two stocks.

How does Elutia compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

NRx Pharmaceuticals presently has a consensus price target of $38.25, indicating a potential upside of 757.62%. Elutia has a consensus price target of $6.00, indicating a potential upside of 531.58%. Given NRx Pharmaceuticals' higher probable upside, research analysts clearly believe NRx Pharmaceuticals is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 17.8% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, NRx Pharmaceuticals had 1 more articles in the media than Elutia. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 3 mentions for Elutia. NRx Pharmaceuticals' average media sentiment score of 1.21 beat Elutia's score of 0.33 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elutia has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	131.37	-$28.62M	-$1.09	N/A
Elutia	$12.46M	3.26	$53.38M	$0.86	1.10

NRx Pharmaceuticals has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, Elutia has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Elutia has a net margin of 312.09% compared to NRx Pharmaceuticals' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Elutia	312.09%	N/A	-53.97%

Summary

Elutia beats NRx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Elutia compare to Acumen Pharmaceuticals?

Elutia (NASDAQ:ELUT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Elutia has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.46M	3.26	$53.38M	$0.86	1.10
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Elutia has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

74.0% of Elutia shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 17.8% of Elutia shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Elutia. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 3 mentions for Elutia. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat Elutia's score of 0.33 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elutia presently has a consensus target price of $6.00, suggesting a potential upside of 531.58%. Acumen Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 258.74%. Given Elutia's stronger consensus rating and higher probable upside, equities analysts clearly believe Elutia is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Elutia has a net margin of 312.09% compared to Acumen Pharmaceuticals' net margin of 0.00%. Elutia's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Summary

Elutia beats Acumen Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Elutia compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Milestone Pharmaceuticals presently has a consensus price target of $7.25, suggesting a potential upside of 489.43%. Elutia has a consensus price target of $6.00, suggesting a potential upside of 531.58%. Given Elutia's higher probable upside, analysts plainly believe Elutia is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elutia has a net margin of 312.09% compared to Milestone Pharmaceuticals' net margin of 0.00%. Elutia's return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Elutia	312.09%	N/A	-53.97%

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 17.8% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Elutia has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A
Elutia	$12.46M	3.26	$53.38M	$0.86	1.10

In the previous week, Elutia had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 3 mentions for Elutia and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat Elutia's score of 0.33 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Milestone Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Elutia has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Summary

Elutia beats Milestone Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELUT vs. The Competition

Export

Metric	Elutia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.65M	$3.65B	$6.81B	$12.41B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	1.10	20.79	27.00	24.19
Price / Sales	3.26	321.78	518.84	94.59
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.46	8.17	10.67	6.26
Net Income	$53.38M	$23.81M	$3.60B	$331.76M
7 Day Performance	4.17%	-1.16%	-0.37%	-1.10%
1 Month Performance	-10.38%	2.60%	1.85%	-1.27%
1 Year Performance	-55.40%	45.44%	25.51%	18.85%

Elutia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELUT Elutia	3.0216 of 5 stars	$0.95 +2.1%	$6.00 +531.6%	-56.1%	$40.65M	$12.46M	1.10	180
ADCT ADC Therapeutics	2.9534 of 5 stars	$1.29 +4.5%	$6.25 +386.4%	-58.5%	$163.44M	$81.36M	N/A	310
ACB Aurora Cannabis	0.9617 of 5 stars	$2.66 flat	N/A	-42.8%	$163.18M	$320.59M	N/A	1,028
NRXP NRx Pharmaceuticals	3.3922 of 5 stars	$4.46 +3.0%	$38.25 +757.6%	+42.2%	$161.59M	$1.23M	N/A	2	News Coverage Positive News
ABOS Acumen Pharmaceuticals	2.4548 of 5 stars	$2.22 -12.3%	$8.00 +260.4%	+47.3%	$160.35M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELUT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elutia (ELUT) Competitors

ELUT vs. ADCT, ACB, NRXP, ABOS, and MIST

How does Elutia compare to ADC Therapeutics?

Summary

How does Elutia compare to Aurora Cannabis?

Summary

How does Elutia compare to NRx Pharmaceuticals?

Summary

How does Elutia compare to Acumen Pharmaceuticals?

Summary

How does Elutia compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elutia (ELUT) Competitors

ELUT vs. ADCT, ACB, NRXP, ABOS, and MIST

How does Elutia compare to ADC Therapeutics?

Do institutionals and insiders believe in ADCT or ELUT?

Which has more volatility and risk, ADCT or ELUT?

Does the media refer more to ADCT or ELUT?

Do analysts rate ADCT or ELUT?

Which has preferable valuation & earnings, ADCT or ELUT?

Is ADCT or ELUT more profitable?

Summary

How does Elutia compare to Aurora Cannabis?

Which has more risk & volatility, ELUT or ACB?

Which has higher earnings and valuation, ELUT or ACB?

Do analysts prefer ELUT or ACB?

Does the media favor ELUT or ACB?

Do insiders & institutionals have more ownership in ELUT or ACB?

Is ELUT or ACB more profitable?

Summary

How does Elutia compare to NRx Pharmaceuticals?

Do analysts prefer NRXP or ELUT?

Do insiders and institutionals believe in NRXP or ELUT?

Does the media refer more to NRXP or ELUT?

Which has better earnings and valuation, NRXP or ELUT?

Which has more volatility & risk, NRXP or ELUT?

Is NRXP or ELUT more profitable?

Summary

How does Elutia compare to Acumen Pharmaceuticals?

Which has preferable earnings and valuation, ELUT or ABOS?

Which has more risk & volatility, ELUT or ABOS?

Do insiders & institutionals hold more shares of ELUT or ABOS?

Does the media prefer ELUT or ABOS?

Do analysts prefer ELUT or ABOS?

Is ELUT or ABOS more profitable?

Summary

How does Elutia compare to Milestone Pharmaceuticals?

Do analysts recommend MIST or ELUT?

Is MIST or ELUT more profitable?

Do institutionals and insiders hold more shares of MIST or ELUT?

Which has preferable earnings & valuation, MIST or ELUT?

Does the media favor MIST or ELUT?

Which has more volatility & risk, MIST or ELUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools